Literature DB >> 3768246

A simple method for determining acetylator phenotype using isoniazid.

A Hutchings, P A Routledge.   

Abstract

A comparison was made between the results of acetylator phenotyping by isoniazid (INH) half-life measurements based on samples taken for 6 h after a single oral dose (200 mg), and by determination of the ratio of acetylisoniazid (Ac.INH) to isoniazid in the 3 h samples. In the 32 subjects, examined, there was complete agreement about classification of the subject as a fast (t1/2 less than 130 min; Ac.INH/INH greater than 1.5) or slow acetylator (t1/2 greater than 130 min; Ac.INH/INH less than 1.5). The single sample test appears to be as reliable as the more time-consuming isoniazid half-life method.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768246      PMCID: PMC1401131          DOI: 10.1111/j.1365-2125.1986.tb02897.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

2.  High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids.

Authors:  A Hutchings; R D Monie; B Spragg; P A Routledge
Journal:  J Chromatogr       Date:  1983-10-14

3.  Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation.

Authors:  R A Ahmad; H J Rogers; M Vandenburg; P Wright
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

4.  Acetylator phenotyping: a comparison of the isoniazid and dapsone tests.

Authors:  A Hanson; A Melander; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

Authors:  K Carr; J A Oates; A S Nies; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

6.  A method to prevent the loss of isoniazid and acetylisoniazid in human plasma.

Authors:  A Hutchings; R D Monie; B Spragg; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

Review 8.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  8 in total
  14 in total

1.  The effects of acute ethanol intake on isoniazid pharmacokinetics.

Authors:  R G Dattani; F Harry; A D Hutchings; P A Routledge
Journal:  Eur J Clin Pharmacol       Date:  2004-10-02       Impact factor: 2.953

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?

Authors:  Hossein Khalili; Simin Dashti-Khavidaki; Mohsen Amini; Reza Mahjub; Mahboobeh Hajiabdolbaghi
Journal:  Eur J Clin Pharmacol       Date:  2010-03       Impact factor: 2.953

4.  The effect of thyrotoxicosis on isoniazid acetylation.

Authors:  M D Littley; A Hutchings; B P Spragg; P A Routledge; J H Lazarus
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

5.  Effect of antacids in didanosine tablet on bioavailability of isoniazid.

Authors:  K Gallicano; J Sahai; G Zaror-Behrens; A Pakuts
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.

Authors:  Alma Tostmann; Charles M Mtabho; Hadija H Semvua; Jossy van den Boogaard; Gibson S Kibiki; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

7.  Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.

Authors:  Erlina Burhan; Carolien Ruesen; Rovina Ruslami; Arum Ginanjar; Hadiarto Mangunnegoro; Purwantyastuti Ascobat; Rogier Donders; Reinout van Crevel; Rob Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

8.  The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.

Authors:  E H Decloedt; J Mwansa-Kambafwile; J-S van der Walt; H McIlleron; P Denti; P Smith; L Wiesner; M Rangaka; R J Wilkinson; G Maartens
Journal:  Int J Tuberc Lung Dis       Date:  2013-03       Impact factor: 2.373

9.  Saliva and plasma concentrations of isoniazid and acetylisoniazid in man.

Authors:  A D Hutchings; R D Monie; B P Spragg; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

10.  Drug acetylation in breast cancer.

Authors:  D J Webster; D Flook; J Jenkins; A Hutchings; P A Routledge
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.